Selank is a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin. It has been studied primarily in neurobehavioral and stress-related research, where it is often discussed for its anxiolytic, nootropic, and neuroregulatory profile. Published work has explored Selank in models involving anxiety, cognition, stress adaptation, and neurochemical signaling, with particular interest in its effects on GABA-related pathways and neurotrophin expression.

Selank is a seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a modified tuftsin analog designed for improved stability and biological activity. Research has examined Selank in relation to neurotransmission, gene-expression changes in the brain, and neuroimmune signaling. Experimental work also suggests that its activity may involve modulation of GABAergic signaling and regulation of neurotrophin-related pathways such as BDNF and TrkB.

Selank has been explored in research involving:

* Anxiety and stress-response models
* Cognitive and learning-related studies
* Neuroprotection and ischemia-related models
* Neuroimmune and cytokine-signaling studies
* Behavioral adaptation and withdrawal-related research

Across the literature, Selank is most commonly positioned as a peptide of interest in studies of anxiolytic signaling, cognitive resilience, and central nervous system adaptation.

The exact mechanism of Selank is still being studied, but current research points to a multi-pathway profile rather than a single receptor target. Experimental findings support possible positive modulation of GABA-related signaling, while other studies suggest downstream effects on BDNF, TrkB, and broader neurotransmission gene expression. Transcriptomic and molecular work has also shown that Selank can alter expression of genes involved in neural communication, immune signaling, and vascular responses under stress or ischemic conditions.

Preclinical studies have examined Selank in rodent models of anxiety, learning, alcohol withdrawal, and cerebral ischemia. In these systems, published findings have reported anxiolytic-like effects, changes in behavioral performance, and neuroprotective or regulatory effects on inflammatory, vascular, and neurotrophic pathways. More recent RNA-seq and proteomic work has expanded interest in Selank by showing system-level changes in gene and protein expression in ischemic brain models, while earlier behavioral studies linked it to improved learning performance in selected animal models.

Zozulya AA, Neznamov GG, Sirota TV, Myasoedov NF. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova, 108(4), 38–48.

Vyunova TV, Andreeva LA, Myasoedov NF. (2018). The molecular aspects of heptapeptide Selank biological activity. Current Medicinal Chemistry, 25(30), 3577–3586.

Volkova A, Krylov B, Andreeva L, et al. (2016). Selank administration affects the expression of some genes involved in neurotransmission in rat frontal cortex. Neurochemical Journal, 10(1), 48–55.

Kasian A, Bagaeva T, Surin A, et al. (2017). Peptide Selank enhances the effect of diazepam in reducing anxiety in experimental models. Journal of Molecular Neuroscience, 61(3), 353–358.

Kozlovskii II, Danchev ND, Vartanyan ME, Neznamov GG. (2003). The optimizing action of the synthetic peptide Selank on learning in rats. Bulletin of Experimental Biology and Medicine, 136(3), 250–253.

To protect experimental integrity, store peptides cold, dry, and shielded from light to minimize oxidation, contamination, and degradation. For near-term use, keep unopened material refrigerated at ≤4 °C (≤39 °F) and limit time at room temperature during handling. Lyophilized (dry) peptides can tolerate short periods at room temperature, but refrigeration is preferred for best stability and longevity. For longer-term storage, keep unmixed material frozen—−18 °C (0 °F) is acceptable, while −80 °C (−112 °F) is optimal for multi-month to multi-year preservation. Avoid frost-free freezers and repeated freeze–thaw cycles, which can accelerate breakdown. If reconstituted (in solution), use sterile buffer (ideally pH 5–6 when feasible), split into aliquots, and freeze (preferably −80 °C (−112 °F)) to reduce handling-related degradation.

All Articles and product information provided on this website are for informational and educational purposes only.